Investors

Event Calendar

 

Upcoming Events

Annual General Meeting 2023

29th June 2023 10:30am CEST Venue: Obseva, Chemin des Aulx 12, 3rd floor, 1228 Plan-les-Ouates, Geneva, Switzerland
Read more


    Half Year 2023 Financial Results week commencing 14 August 2023

    Read more


      Past Events

      8th Annual Sofinnova Japan Biopharma Partnering Conference – Tokyo, Japan

      October 27, 2015

      Read more

      15th Annual Biotech in Europe Forum – Basel, Switzerland

      September 29, 2015

      Read more

      BIO-Europe Spring 2015® – Paris, France

      March 10, 2015

      Read more
      1 29 30 31

      General Meetings

      ObsEva Annual General Meeting 2019

      May 8, 2019

      Read more

      ObsEva Annual General Meeting 2018

      May 9, 2018

      Read more
      1 2 3 4
       
       

      Sign up for news

       
       

        * Type:


        InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












        Read our privacy policy here.


         

        Are you sure you want to leave ObsEva.com?

        We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

        Continue to link

        Disclaimer

        Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

        Continue

        Disclaimer

        Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

        Continue